Literature DB >> 1977935

Torsades de pointes occurring in association with terfenadine use.

B P Monahan1, C L Ferguson, E S Killeavy, B K Lloyd, J Troy, L R Cantilena.   

Abstract

Torsades de pointes is a form of polymorphic ventricular tachycardia that is associated with prolongation of the QT interval. Although found in many clinical settings, torsades de pointes is most often drug induced. This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone. Measured serum concentrations of terfenadine and its main metabolite showed excessive levels of parent terfenadine and proportionately reduced concentrations of metabolite, suggesting inhibition of terfenadine metabolism. We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977935

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  121 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization.

Authors:  A J Moss; W Zareba; J Benhorin; J P Couderc; H Kennedy; E Locati-Heilbron; P Maison-Blanche
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-10       Impact factor: 1.468

3.  The electrocardiogram: from Einthoven to molecular genetics.

Authors:  A J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-07       Impact factor: 1.468

4.  Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction.

Authors:  Corina Dota; Bo Skallefell; Nils Edvardsson; Gunnar Fager
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

5.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 6.  Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors:  G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 7.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

9.  Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

10.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.